MediGene and Will-Pharma Sign Agreement for the Commercialization of Veregen in Benelux

15-Mar-2011 - Belgium

MediGene AG  has signed an exclusive license and supply agreement with Will-Pharma for the commercialization and marketing of Veregen® ointment in Belgium, the Netherlands and Luxembourg. Will-Pharma will market, promote and distribute the drug for the treatment of genital warts. Further financial details of the agreement were not disclosed.

MediGene has already entered into several marketing partnerships for Veregen®, e.g. with Nycomed for the USA, with Abbott for Germany, Austria, and Switzerland, with Expanscience for France, with Juste for Spain and Portugal as well as with a number of other partners across Europe, Latin America and Asia. MediGene is planning to continue this global licensing strategy.

Other news from the department research and development

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?